AstraZeneca's Calquence has gained a positive nod from the European Medicines Agency for first-line treatment of untreated mantle cell lymphoma, showing a 27% lower risk of disease progression.
AstraZeneca's Imfinzi gained FDA approval as the first perioperative immunotherapy for muscle-invasive bladder cancer, showing a 32% lower recurrence risk and 25% lower death risk in trials.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.